Executive Director, Cell Therapy Medical Communications Lead

Executive Director, Worldwide Cell Therapy Medical Communications Lead

Position Summary:

The Executive Director, Medical Communications Lead is the Cell Therapy Medical (CT Medical) owner of external scientific communications and publication governance for the Cell Therapy portfolio and a strategic partner to cross‑functional leaders across the end‑to‑end cell therapy value chain. Reporting to the SVP, Head Cell Therapy Medical, this role ensures timely, compliant and high‑quality dissemination of data through publications, congresses, scientific content and selected reactive communications while aligning communications to CT Medical strategy, evidence generation plans and operational realities.

The role serves as steward of reputational, journal, investigator and compliance risk for CT Medical and drives continuous improvement in governance and operating models to enable an integrated, high‑performing Cell Therapy Medical ecosystem.

• Lead CT Medical scientific disclosure strategy for the Cell Therapy portfolio across asset life cycles, including manuscripts, abstracts, posters, oral presentations and selected reactive materials.
• Represent CT Medical as the primary Medical Communications partner to Global Development, Clinical Operations, Translational Medicine, Commercial, Market Access, Patient Safety, Regulatory, Quality and Manufacturing/Supply, ensuring integrated, patient‑centered scientific communications that reflect the realities of cell therapy development and delivery.
• Ensure external communications align with development strategy, evidence generation plans, asset maturity and enterprise priorities while meeting ethical and compliance standards.
• Serve as accountable owner of reputational, journal, investigator and compliance risk related to scientific communications, including escalation and decision support for complex or novel scenarios.
• Serve as CT Medical lead for publication governance and policy interpretation; establish clear CT Medical decision rights, operating cadence and cross‑functional expectations to enable speed with rigor.
• Drive adoption of best practices, tools and operating models to improve Medical Communications effectiveness and efficiency, including standardized workflows across indications and assets.
• Establish CT Medical standards for scientific publications, scientific content and independent medical education in alignment with applicable SOPs and external codes (e.g., GPP) across the Cell Therapy portfolio.
• Build and sustain Medical Communications leadership capability through talent development and succession planning; coach teams to operate effectively in a complex, matrixed, global environment.
• Lead and develop global Medical Communications teams across geographies and time zones; cultivate a culture of collaboration, inclusion and continuous improvement.

• Good Publication Practice (GPP), Sunshine Act and post‑marketing scientific communications guidance.
• Deep expertise in external scientific communications across the asset lifecycle, including complex modalities (cell therapy/advanced therapies strongly preferred).
• Understanding of the cell therapy ecosystem and end‑to‑end value chain (clinical development, treatment centers, manufacturing/quality interfaces) and the implications for scientific disclosure and stakeholder engagement.

• Executive‑level scientific and strategic communication skills.
• Ability to influence in complex, global, matrixed environments.
• Experience managing global teams and operating in enterprise settings.

• Enterprise mindset, change leadership orientation, high learning agility.
• Inclusive, collaborative leadership style aligned with BMS values.

$255,480 - $309,587

The starting compensation range above is for a full‑time employee (FTE) basis. Additional incentive cash and stock opportunities (based on eligibility) may be available. The starting pay rate takes into account job characteristics such as required skills, location, work schedule and experience. Final, individual compensation will be determined based on demonstrated…